ChemoMetec A/S

CPSE:CHEMM Stock Report

Market Cap: DKK 6.7b

ChemoMetec Valuation

Is CHEMM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CHEMM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CHEMM (DKK381.8) is trading above our estimate of future cash flow value (DKK365.08)

Significantly Below Future Cash Flow Value: CHEMM is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CHEMM?

Key metric: As CHEMM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CHEMM. This is calculated by dividing CHEMM's market cap by their current earnings.
What is CHEMM's PE Ratio?
PE Ratio37.5x
EarningsDKK 177.03m
Market CapDKK 6.68b

Price to Earnings Ratio vs Peers

How does CHEMM's PE Ratio compare to its peers?

The above table shows the PE ratio for CHEMM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.8x
GUBRA Gubra
3.4x-42.61%DKK 5.5b
BAVA Bavarian Nordic
11.9x3.08%DKK 13.9b
GXI Gerresheimer
36.5x42.66%€853.1m
AKUMS Akums Drugs and Pharmaceuticals
35.5x28.80%₹90.7b
CHEMM ChemoMetec
37.5x18.00%DKK 6.7b

Price-To-Earnings vs Peers: CHEMM is expensive based on its Price-To-Earnings Ratio (37.5x) compared to the peer average (21.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does CHEMM's PE Ratio compare vs other companies in the European Life Sciences Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CHEMM 37.5xIndustry Avg. 34.0xNo. of Companies3PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CHEMM is expensive based on its Price-To-Earnings Ratio (37.5x) compared to the Global Life Sciences industry average (34x).

Price to Earnings Ratio vs Fair Ratio

What is CHEMM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHEMM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.5x
Fair PE Ratio19.4x

Price-To-Earnings vs Fair Ratio: CHEMM is expensive based on its Price-To-Earnings Ratio (37.5x) compared to the estimated Fair Price-To-Earnings Ratio (19.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CHEMM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 381.80
DKK 546.25
+43.07%
17.65%DKK 650.00DKK 450.00n/a4
Jun ’27DKK 357.40
DKK 546.25
+52.84%
17.65%DKK 650.00DKK 450.00n/a4
May ’27DKK 326.00
DKK 615.00
+88.65%
16.45%DKK 725.00DKK 450.00n/a4
Apr ’27DKK 309.00
DKK 640.00
+107.12%
9.71%DKK 725.00DKK 550.00n/a4
Mar ’27DKK 420.40
DKK 753.75
+79.29%
17.70%DKK 900.00DKK 550.00n/a4
Feb ’27DKK 609.50
DKK 866.25
+42.12%
9.99%DKK 970.00DKK 730.00n/a4
Jan ’27DKK 687.50
DKK 870.00
+26.55%
9.28%DKK 970.00DKK 745.00n/a4
Dec ’26DKK 764.00
DKK 870.00
+13.87%
9.28%DKK 970.00DKK 745.00n/a4
Nov ’26DKK 791.00
DKK 793.33
+0.29%
9.55%DKK 890.00DKK 705.00n/a3
Oct ’26DKK 648.50
DKK 676.67
+4.34%
1.84%DKK 690.00DKK 660.00n/a3
Sep ’26DKK 523.00
DKK 623.33
+19.18%
8.72%DKK 680.00DKK 550.00n/a3
Aug ’26DKK 486.00
DKK 598.33
+23.11%
9.85%DKK 640.00DKK 515.00n/a3
Jul ’26DKK 562.50
DKK 598.33
+6.37%
9.85%DKK 640.00DKK 515.00n/a3
Jun ’26DKK 528.00
DKK 598.33
+13.32%
9.85%DKK 640.00DKK 515.00DKK 357.403
May ’26DKK 473.40
DKK 652.50
+37.83%
3.45%DKK 675.00DKK 630.00DKK 326.002
Apr ’26DKK 507.00
DKK 652.50
+28.70%
3.45%DKK 675.00DKK 630.00DKK 309.002
Mar ’26DKK 581.00
DKK 652.50
+12.31%
3.45%DKK 675.00DKK 630.00DKK 420.402
Feb ’26DKK 560.00
DKK 582.50
+4.02%
5.58%DKK 615.00DKK 550.00DKK 609.502
Jan ’26DKK 486.20
DKK 545.00
+12.09%
0.92%DKK 550.00DKK 540.00DKK 687.502
Dec ’25DKK 473.60
DKK 545.00
+15.08%
0.92%DKK 550.00DKK 540.00DKK 764.002
Nov ’25DKK 408.00
DKK 438.33
+7.43%
16.19%DKK 505.00DKK 340.00DKK 791.003
Oct ’25DKK 397.60
DKK 436.67
+9.83%
16.79%DKK 505.00DKK 335.00DKK 648.503
Sep ’25DKK 374.60
DKK 462.50
+23.47%
2.70%DKK 475.00DKK 450.00DKK 523.002
Aug ’25DKK 377.40
DKK 437.50
+15.92%
8.57%DKK 475.00DKK 400.00DKK 486.002
Jul ’25DKK 301.40
DKK 437.50
+45.16%
8.57%DKK 475.00DKK 400.00DKK 562.502
Jun ’25DKK 363.20
DKK 437.50
+20.46%
8.57%DKK 475.00DKK 400.00DKK 528.002
DKK 546.25
Fair Value
30.1% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 16:49
End of Day Share Price 2026/06/10 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ChemoMetec A/S is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mads Brinkmann AndersenBerenberg
Kallum TitchmarshBofA Global Research
Simon LarssonDanske Bank